Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 34

1.

Erythrocyte-encapsulated asparaginase (eryaspase) combined with chemotherapy in second-line treatment of advanced pancreatic cancer: An open-label, randomized Phase IIb trial.

Hammel P, Fabienne P, Mineur L, Metges JP, Andre T, De La Fouchardiere C, Louvet C, El Hajbi F, Faroux R, Guimbaud R, Tougeron D, Bouche O, Lecomte T, Rebischung C, Tournigand C, Cros J, Kay R, Hamm A, Gupta A, Bachet JB, El Hariry I.

Eur J Cancer. 2020 Jan;124:91-101. doi: 10.1016/j.ejca.2019.10.020. Epub 2019 Nov 21.

2.

Ganetespib, an HSP90 inhibitor, kills Epstein-Barr virus (EBV)-infected B and T cells and reduces the percentage of EBV-infected cells in the blood.

Shatzer A, Ali MA, Chavez M, Dowdell K, Lee MJ, Tomita Y, El-Hariry I, Trepel JB, Proia DA, Cohen JI.

Leuk Lymphoma. 2017 Apr;58(4):923-931. doi: 10.1080/10428194.2016.1213823. Epub 2016 Aug 11.

3.

Geographic variation in human papillomavirus-related oropharyngeal cancer: Data from 4 multinational randomized trials.

Mehanna H, Franklin N, Compton N, Robinson M, Powell N, Biswas-Baldwin N, Paleri V, Hartley A, Fresco L, Al-Booz H, Junor E, El-Hariry I, Roberts S, Harrington K, Ang KK, Dunn J, Woodman C.

Head Neck. 2016 Apr;38 Suppl 1:E1863-9. doi: 10.1002/hed.24336. Epub 2016 Jan 8.

4.

Postoperative Adjuvant Lapatinib and Concurrent Chemoradiotherapy Followed by Maintenance Lapatinib Monotherapy in High-Risk Patients With Resected Squamous Cell Carcinoma of the Head and Neck: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study.

Harrington K, Temam S, Mehanna H, D'Cruz A, Jain M, D'Onofrio I, Manikhas G, Horvath Z, Sun Y, Dietzsch S, Dubinsky P, Holeckova P, El-Hariry I, Franklin N, Biswas-Baldwin N, Legenne P, Wissel P, Netherway T, Farrell J, Ellis C, Wang-Silvanto J, Amonkar M, Ahmed N, Santillana S, Bourhis J.

J Clin Oncol. 2015 Dec 10;33(35):4202-9. doi: 10.1200/JCO.2015.61.4370. Epub 2015 Nov 2.

PMID:
26527790
5.

A phase II open-label study of ganetespib, a novel heat shock protein 90 inhibitor for patients with metastatic breast cancer.

Jhaveri K, Chandarlapaty S, Lake D, Gilewski T, Robson M, Goldfarb S, Drullinsky P, Sugarman S, Wasserheit-Leiblich C, Fasano J, Moynahan ME, D'Andrea G, Lim K, Reddington L, Haque S, Patil S, Bauman L, Vukovic V, El-Hariry I, Hudis C, Modi S.

Clin Breast Cancer. 2014 Jun;14(3):154-60. doi: 10.1016/j.clbc.2013.12.012. Epub 2013 Dec 28.

PMID:
24512858
6.

Preclinical activity profile and therapeutic efficacy of the HSP90 inhibitor ganetespib in triple-negative breast cancer.

Proia DA, Zhang C, Sequeira M, Jimenez JP, He S, Spector N, Shapiro GI, Tolaney S, Nagai M, Acquaviva J, Smith DL, Sang J, Bates RC, El-Hariry I.

Clin Cancer Res. 2014 Jan 15;20(2):413-24. doi: 10.1158/1078-0432.CCR-13-2166. Epub 2013 Oct 30.

7.

Antiangiogenic effects of ganetespib in colorectal cancer mediated through inhibition of HIF-1α and STAT-3.

Nagaraju GP, Park W, Wen J, Mahaseth H, Landry J, Farris AB, Willingham F, Sullivan PS, Proia DA, El-Hariry I, Taliaferro-Smith L, Diaz R, El-Rayes BF.

Angiogenesis. 2013 Oct;16(4):903-17. doi: 10.1007/s10456-013-9364-7. Epub 2013 Jul 10. Erratum in: Angiogenesis. 2013 Oct;16(4):919. Ganji, Purnachandra Nagaraju [corrected to Nagaraju, Ganji Purnachandra].

PMID:
23838996
8.

A multicenter phase II study of ganetespib monotherapy in patients with genotypically defined advanced non-small cell lung cancer.

Socinski MA, Goldman J, El-Hariry I, Koczywas M, Vukovic V, Horn L, Paschold E, Salgia R, West H, Sequist LV, Bonomi P, Brahmer J, Chen LC, Sandler A, Belani CP, Webb T, Harper H, Huberman M, Ramalingam S, Wong KK, Teofilovici F, Guo W, Shapiro GI.

Clin Cancer Res. 2013 Jun 1;19(11):3068-77. doi: 10.1158/1078-0432.CCR-12-3381. Epub 2013 Apr 3.

9.

Targeted inhibition of the molecular chaperone Hsp90 overcomes ALK inhibitor resistance in non-small cell lung cancer.

Sang J, Acquaviva J, Friedland JC, Smith DL, Sequeira M, Zhang C, Jiang Q, Xue L, Lovly CM, Jimenez JP, Shaw AT, Doebele RC, He S, Bates RC, Camidge DR, Morris SW, El-Hariry I, Proia DA.

Cancer Discov. 2013 Apr;3(4):430-43. doi: 10.1158/2159-8290.CD-12-0440. Epub 2013 Mar 26.

10.

A first in human, safety, pharmacokinetics, and clinical activity phase I study of once weekly administration of the Hsp90 inhibitor ganetespib (STA-9090) in patients with solid malignancies.

Goldman JW, Raju RN, Gordon GA, El-Hariry I, Teofilivici F, Vukovic VM, Bradley R, Karol MD, Chen Y, Guo W, Inoue T, Rosen LS.

BMC Cancer. 2013 Mar 25;13:152. doi: 10.1186/1471-2407-13-152.

11.

Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

Harrington K, Berrier A, Robinson M, Remenar E, Housset M, de Mendoza FH, Fayette J, Mehanna H, El-Hariry I, Compton N, Franklin N, Biswas-Baldwin N, Lau M, Legenne P, Kumar R.

Eur J Cancer. 2013 May;49(7):1609-18. doi: 10.1016/j.ejca.2012.11.023. Epub 2012 Dec 19.

PMID:
23265705
12.

EORTC 24051: unexpected side effects in a phase I study of TPF induction chemotherapy followed by chemoradiation with lapatinib, a dual EGFR/ErbB2 inhibitor, in patients with locally advanced resectable larynx and hypopharynx squamous cell carcinoma.

Lalami Y, Specenier PM, Awada A, Lacombe D, Liberatoscioli C, Fortpied C, El-Hariry I, Bogaerts J, Andry G, Langendijk JA, Vermorken JB.

Radiother Oncol. 2012 Nov;105(2):238-40. doi: 10.1016/j.radonc.2012.08.006. Epub 2012 Sep 16.

PMID:
22989664
13.

Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer--systematic review and meta-analysis of trends by time and region.

Mehanna H, Beech T, Nicholson T, El-Hariry I, McConkey C, Paleri V, Roberts S.

Head Neck. 2013 May;35(5):747-55. doi: 10.1002/hed.22015. Epub 2012 Jan 20. Review.

PMID:
22267298
14.

Effects of lapatinib monotherapy: results of a randomised phase II study in therapy-naive patients with locally advanced squamous cell carcinoma of the head and neck.

Del Campo JM, Hitt R, Sebastian P, Carracedo C, Lokanatha D, Bourhis J, Temam S, Cupissol D, De Raucourt D, Maroudias N, Nutting CM, Compton N, Midwinter D, Downie L, Biswas-Baldwin N, El-Hariry I, Harrington KJ.

Br J Cancer. 2011 Aug 23;105(5):618-27. doi: 10.1038/bjc.2011.237. Epub 2011 Aug 9.

15.

Prevalence and incidence of acute and chronic comorbidity in patients with squamous cell carcinoma of the head and neck.

Landis SH, El-Hariry IA, van Herk-Sukel MP, van den Haak P, Janssen-Heijnen ML, Penning-van Beest FJ, Herings RM.

Head Neck. 2012 Feb;34(2):238-44. doi: 10.1002/hed.21720. Epub 2011 May 23.

PMID:
21608062
16.

Thrombopoietin receptor levels in tumor cell lines and primary tumors.

Erickson-Miller CL, Chadderton A, Gibbard A, Kirchner J, Pillarisetti K, Baker K, Pandite L, El-Hariry I, Mostafa Kamel Y, Liu Y, Martin AM, Messam C.

J Oncol. 2010;2010:135354. doi: 10.1155/2010/135354. Epub 2010 Dec 28.

17.

A Bayesian hierarchical model for DCE-MRI to evaluate treatment response in a phase II study in advanced squamous cell carcinoma of the head and neck.

Whitcher B, Schmid VJ, Collins DJ, Orton MR, Koh DM, Diaz de Corcuera I, Parera M, del Campo JM, DeSouza NM, Leach MO, Harrington K, El-Hariry IA.

MAGMA. 2011 Apr;24(2):85-96. doi: 10.1007/s10334-010-0238-3. Epub 2011 Jan 4.

PMID:
21203797
18.

Weekly volume and dosimetric changes during chemoradiotherapy with intensity-modulated radiation therapy for head and neck cancer: a prospective observational study.

Bhide SA, Davies M, Burke K, McNair HA, Hansen V, Barbachano Y, El-Hariry IA, Newbold K, Harrington KJ, Nutting CM.

Int J Radiat Oncol Biol Phys. 2010 Apr;76(5):1360-8. doi: 10.1016/j.ijrobp.2009.04.005.

PMID:
20338474
19.

Amplification of epidermal growth factor receptor gene in renal cell carcinoma.

El-Hariry I, Powles T, Lau MR, Sternberg CN, Ravaud A, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Barthel F, Machiels JP, Patel P, Kreuser ED, Hawkins RE.

Eur J Cancer. 2010 Mar;46(5):859-62. doi: 10.1016/j.ejca.2010.01.011. Epub 2010 Feb 16.

PMID:
20167476
20.

Correlation between dose to the pharyngeal constrictors and patient quality of life and late dysphagia following chemo-IMRT for head and neck cancer.

Bhide SA, Gulliford S, Kazi R, El-Hariry I, Newbold K, Harrington KJ, Nutting CM.

Radiother Oncol. 2009 Dec;93(3):539-44. doi: 10.1016/j.radonc.2009.09.017. Epub 2009 Oct 31.

PMID:
19883951
21.

A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma.

Wülfing C, Machiels JP, Richel DJ, Grimm MO, Treiber U, De Groot MR, Beuzeboc P, Parikh R, Pétavy F, El-Hariry IA.

Cancer. 2009 Jul 1;115(13):2881-90. doi: 10.1002/cncr.24337.

22.

Head and neck cancer in South East England between 1995-1999 and 2000-2004: An estimation of incidence and distribution by site, stage and histological type.

Doobaree IU, Landis SH, Linklater KM, El-Hariry I, Moller H, Tyczynski J.

Oral Oncol. 2009 Sep;45(9):809-14. doi: 10.1016/j.oraloncology.2008.12.009. Epub 2009 Feb 28.

PMID:
19251472
23.

Phase I study of lapatinib in combination with chemoradiation in patients with locally advanced squamous cell carcinoma of the head and neck.

Harrington KJ, El-Hariry IA, Holford CS, Lusinchi A, Nutting CM, Rosine D, Tanay M, Deutsch E, Matthews J, D'Ambrosio C, Turner SJ, Pandeshwara JS, Bourhis J.

J Clin Oncol. 2009 Mar 1;27(7):1100-7. doi: 10.1200/JCO.2008.17.5349. Epub 2009 Jan 26.

PMID:
19171712
24.
25.

Lapatinib versus hormone therapy in patients with advanced renal cell carcinoma: a randomized phase III clinical trial.

Ravaud A, Hawkins R, Gardner JP, von der Maase H, Zantl N, Harper P, Rolland F, Audhuy B, Machiels JP, Pétavy F, Gore M, Schöffski P, El-Hariry I.

J Clin Oncol. 2008 May 10;26(14):2285-91. doi: 10.1200/JCO.2007.14.5029.

PMID:
18467719
26.

Adhesion molecules: opportunities for modulation and a paradigm for novel therapeutic approaches in cancer.

El-Hariry I, Pignatelli M.

Expert Opin Investig Drugs. 1997 Oct;6(10):1465-78.

PMID:
15989513
27.

FGF-1 and FGF-2 regulate the expression of E-cadherin and catenins in pancreatic adenocarcinoma.

El-Hariry I, Pignatelli M, Lemoine NR.

Int J Cancer. 2001 Dec 1;94(5):652-61.

28.

A phase II trial of oral eniluracil/5-fluorouracil in patients with inoperable hepatocellular carcinoma.

Llovet JM, Ruff P, Tassopoulos N, Castells L, Bruix J, El-Hariry I, Peachey M.

Eur J Cancer. 2001 Jul;37(11):1352-8.

PMID:
11435064
29.

FGF-1 and FGF-2 modulate the E-cadherin/catenin system in pancreatic adenocarcinoma cell lines.

El-Hariry I, Pignatelli M, Lemoine NR.

Br J Cancer. 2001 Jun 15;84(12):1656-63.

30.

Characterization of the E-cadherin-catenin complexes in pancreatic carcinoma cell lines.

El-Hariry I, Jordinson M, Lemoine N, Pignatelli M.

J Pathol. 1999 Jun;188(2):155-62.

PMID:
10398158
31.
32.

Phosphorylation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor.

Liu D, el-Hariry I, Karayiannakis AJ, Wilding J, Chinery R, Kmiot W, McCrea PD, Gullick WJ, Pignatelli M.

Lab Invest. 1997 Dec;77(6):557-63.

PMID:
9426392
33.

Expression of E-cadherin-associated molecules (alpha-, beta-, and gamma-catenins and p120) in colorectal polyps.

Valizadeh A, Karayiannakis AJ, el-Hariry I, Kmiot W, Pignatelli M.

Am J Pathol. 1997 Jun;150(6):1977-84.

34.

Fibroblast growth factor 1 and fibroblast growth factor 2 immunoreactivity in gastrointestinal tumours.

el-Hariry I, Pignatelli M, Lemoine N.

J Pathol. 1997 Jan;181(1):39-45.

PMID:
9072001

Supplemental Content

Loading ...
Support Center